|
Feb 21
|
ChromaDex And 2 Other Undervalued Small Caps In US With Insider Buying
|
|
Feb 20
|
Pick These 4 Stocks With Solid Net Profit Margin to Boost Return
|
|
Jan 3
|
US Stocks That May Be Priced Below Intrinsic Value In January 2025
|
|
Sep 26
|
ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
|
|
Sep 26
|
Is ChromaDex (CDXC) Stock Outpacing Its Medical Peers This Year?
|
|
Sep 20
|
ChromaDex Appoints Ozan Pamir as Chief Financial Officer
|
|
Sep 17
|
3 US Growth Companies With High Insider Ownership
|
|
Sep 15
|
Insiders own 31% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 42% of the company
|
|
Jul 24
|
ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
|
|
Jul 23
|
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
|
|
Jul 16
|
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
|
|
Jun 24
|
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
|
|
Jun 10
|
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
|
|
Jun 7
|
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
|
|
May 10
|
ChromaDex Corp (CDXC) Q1 2024 Earnings: Aligns with EPS Projections, Misses Revenue Estimates
|
|
May 9
|
ChromaDex Corporation (NASDAQ:CDXC) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Q1 2024 Chromadex Corp Earnings Call
|
|
May 9
|
ChromaDex Corp (CDXC) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ...
|
|
May 8
|
ChromaDex Corporation Reports First Quarter 2024 Financial Results
|
|
May 6
|
An Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 43% Undervalued
|